[go: up one dir, main page]

RU2014120624A - METHOD FOR TREATING A STROKE - Google Patents

METHOD FOR TREATING A STROKE Download PDF

Info

Publication number
RU2014120624A
RU2014120624A RU2014120624/15A RU2014120624A RU2014120624A RU 2014120624 A RU2014120624 A RU 2014120624A RU 2014120624/15 A RU2014120624/15 A RU 2014120624/15A RU 2014120624 A RU2014120624 A RU 2014120624A RU 2014120624 A RU2014120624 A RU 2014120624A
Authority
RU
Russia
Prior art keywords
stroke
cytokine
treating
basic
raleikin
Prior art date
Application number
RU2014120624/15A
Other languages
Russian (ru)
Other versions
RU2571282C1 (en
Inventor
Александр Митрофанович Ищенко
Андрей Семенович Симбирцев
Татьяна Олеговна Антипова
Александр Евгеньевич Полоцкий
Александр Владимирович Жахов
Наталья Васильевна Пигарева
Максим Алексеевич ШЕВЦОВ
Original Assignee
Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства filed Critical Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства
Priority to RU2014120624/15A priority Critical patent/RU2571282C1/en
Publication of RU2014120624A publication Critical patent/RU2014120624A/en
Application granted granted Critical
Publication of RU2571282C1 publication Critical patent/RU2571282C1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ базисной терапии инсульта, включающий базисную и дифференцированную терапию, а также введение в организм больного цитокина, отличающийся тем, что в качестве цитокина вводят подкожно антагонист рецептора интерлейкина-1 препарат Ралейкин в дозе 15-25 мг на килограмм массы тела.A method for the basic treatment of stroke, including basic and differential therapy, as well as the introduction of a cytokine into the patient’s body, characterized in that the Raleikin receptor antagonist is administered subcutaneously as a cytokine at a dose of 15-25 mg per kilogram of body weight.

Claims (1)

Способ базисной терапии инсульта, включающий базисную и дифференцированную терапию, а также введение в организм больного цитокина, отличающийся тем, что в качестве цитокина вводят подкожно антагонист рецептора интерлейкина-1 препарат Ралейкин в дозе 15-25 мг на килограмм массы тела. A method for the basic treatment of stroke, including basic and differential therapy, as well as the introduction of a cytokine into the patient’s body, characterized in that the Raleikin receptor antagonist is administered subcutaneously as a cytokine at a dose of 15-25 mg per kilogram of body weight.
RU2014120624/15A 2014-05-22 2014-05-22 Method for stroke treatment RU2571282C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2014120624/15A RU2571282C1 (en) 2014-05-22 2014-05-22 Method for stroke treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014120624/15A RU2571282C1 (en) 2014-05-22 2014-05-22 Method for stroke treatment

Publications (2)

Publication Number Publication Date
RU2014120624A true RU2014120624A (en) 2015-11-27
RU2571282C1 RU2571282C1 (en) 2015-12-20

Family

ID=54753390

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014120624/15A RU2571282C1 (en) 2014-05-22 2014-05-22 Method for stroke treatment

Country Status (1)

Country Link
RU (1) RU2571282C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2659674C1 (en) * 2017-07-17 2018-07-03 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Method for treatment of cerebrovascular brain disorders (options)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218328A1 (en) * 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Preventive therapy for acute stroke
DE102004013294A1 (en) * 2004-03-18 2006-02-23 Thomas Dr. Stratz Use of tropisetron and/or 5-hydroxy tryptophan-3-receptor-antagonist to reduce apoplectic condition in an infarct area by blocking serotonin-3-receptor, down-regulate inflammation process and strengthen the serotonin receptor expression
RU2268064C1 (en) * 2005-02-14 2006-01-20 Федеральное государственное образовательное учреждение высшего профессионального образования "Чувашский государственный университет им. И.Н. Ульянова" Method for treating acute cerebral stroke cases

Also Published As

Publication number Publication date
RU2571282C1 (en) 2015-12-20

Similar Documents

Publication Publication Date Title
MX2021002321A (en) Novel methods.
MX393855B (en) COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
MX2022003072A (en) Use of pridopidine for treating functional decline.
MX2017005875A (en) Methods for treating ocular diseases.
MX2018001659A (en) Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment.
MY186977A (en) Tetrasubstituted alkene compounds and their use
MX2022011334A (en) Treatment of fabry disease in ert-naãve and ert-experienced patients.
EA201892190A1 (en) TREATMENT OF PSORIASIS WITH ANTI-BODY TO IL-12 AND / OR IL-23 WITH THE GROWTH OF THE INTERVAL BETWEEN THE INTRODUCTION OF DOSE
MX2021000289A (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia.
WO2016051398A8 (en) Patient-specific immunotherapy for treating heterogeneous tumors
PH12015502500B1 (en) Bacteriophage therapy
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
EA201792294A1 (en) COMBINED TREATMENT (OPTIONS) WITH THE USE OF SERIBANTUMAB
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
WO2018013855A3 (en) Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines
RU2018114457A (en) TREATMENT OF SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER
PH12017500617A1 (en) Dosage regimen for pegylated interferon
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
RU2014120624A (en) METHOD FOR TREATING A STROKE
EA201992852A1 (en) DOSAGE DIAGRAM FOR TESETAXEL AND CAPETSITABINE
NZ760040A (en) Methods of treating brain tumors using combination therapy
MX2018011607A (en) Sultiame for the treatment of sleep apnea.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160523

NF4A Reinstatement of patent

Effective date: 20170424